Jim Cramer Endorses 3M as a Growth Stock Once More

Published 5 hours agoMMM

Jim Cramer Endorses 3M as a Growth Stock Once More

Jim Cramer has given a bullish endorsement of 3M Company, suggesting that the company may be poised for a resurgence as a growth stock. This optimism comes on the heels of 3M's impressive fourth-quarter results, where the company reported an impressive increase in adjusted gross margins by 280 basis points. Alongside this, 3M provided a positive outlook with a forecasted sales growth of 2% to 3% for 2025, outdoing analysts' expectations of merely 1.6%. This confident financial guidance is a telling indicator of 3M's steady trajectory.

In addition to strong financial outcomes, Cramer also highlighted the leadership under CEO William M. Brown, commending his decisive and effective management. Cramer envisions 3M's return to being regarded as a growth stock similar to its historical performance highs. As insiders expect, such positive developments are likely to lead Wall Street analysts to reconsider and potentially upgrade their ratings for 3M. As Insider Monkey reported, this comes amidst the advantageous backdrop of a reliable leadership steering the company toward greater heights.

Moreover, the appeal of 3M extends to dividend-seeking investors, offering a 1.90% dividend yield that adds to the attractiveness of holding the stock. Cramer's favorable views, highlighted by sources like Insider Monkey and Invezz, underscore 3M's potential for delivering both growth and income. As 3M continues to advance its strategic initiatives, the market keenly watches its capacity to maintain this growth momentum.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Ford CEO Jim Farley Urges for Balanced U.S. Tariff Policies

Ford CEO Jim Farley Urges for Balanced U.S. Tariff Policies

Ford CEO Jim Farley has recently called for comprehensive U.S. trade policies that promote both exports and American production. Farley highlighted the disparity in tariffs, noting how countries like Japan and South Korea face far less restrictive duties compared to the proposed 25% tariffs for Canada and Mexico. His push for level playing field aims to mitigate the financial instability and production disruptions currently affecting the automotive industry, NBC Chicago reported. Farley is particularly concerned about the "cost and chaos" introduced by existing tariffs, which have complicated the industry landscape, per Axios. Although recent tariff relief measures have been introduced, Farley remains cautious as the current lack of policy clarity delays crucial capital investments and product decisions. Export promotion, in his view, is vital to enhancing the global competitiveness of American vehicles. In response to these challenges, Ford is considering expanding its domestic manufacturing presence. This potential move toward increasing their U.S. footprint reflects a strategic shift to counterbalance the rising costs associated with imports. By focusing on domestic production, Ford seeks to strengthen its operations in the face of uncertain trade policies.

GeneDx Holdings Corp. Stock Plummets Amid Revised Forecasts

GeneDx Holdings Corp. Stock Plummets Amid Revised Forecasts

23 minutes agoWGS

GeneDx Holdings Corp. (NASDAQ: WGS) is seeing a notable drop in its stock price, falling 37.95% to $72.59 as of April 30, 2025. The plunge comes in the wake of analysts downgrading their revenue estimates for the company as well as revising price targets downward. Analysts have reduced their revenue forecasts for GeneDx, predicting earnings of $222 million for 2024, a 7.6% rise from the previous year but a drop from earlier expectations of $248 million. They've also cut the consensus price target by 27% to $7.25, according to simplywall.st. Meanwhile, insider activity shows CEO Katherine Stueland recently sold 2,154 shares at an average price of $66.60 per share. Despite the current downswing, GeneDx reported a positive Q3 2024 financial performance, with earnings per share of $0.04, beating the projected $0.21 loss. The company posted a revenue of $76.90 million, marking a 44.3% increase year-over-year. Additionally, GeneDx maintains a debt-to-equity ratio of 0.25 and a quick ratio of 2.22, indicating manageable debt levels and solid liquidity, as reported by marketbeat.com.

Lincoln Electric Sets Cautious Tone for 2025 with Flat Sales

Lincoln Electric Sets Cautious Tone for 2025 with Flat Sales

54 minutes agoLECO

Lincoln Electric has outlined a cautious forecast for 2025, with expectations of flat organic sales for the year. This assessment comes as the company anticipates challenges within the global economy, particularly concerning supply chain issues and demand fluctuations in key markets. In response to these challenges, Lincoln Electric plans to increase prices within a mid-single-digit percentage range. This strategy aims to counteract potential cost pressures and maintain the company's financial stability. As part of their strategic focus, Lincoln Electric is honing in on cost management and operational efficiency to effectively navigate the expected market conditions. Despite these guarded predictions for 2025, Lincoln Electric remains committed to achieving stable financial performance. As Reuters has noted, the company intends to leverage strategic pricing and cost control measures effectively, emphasizing a proactive approach to the anticipated economic challenges.

Analysts See Growth Potential in Neurocrine Biosciences

Analysts See Growth Potential in Neurocrine Biosciences

1 hours agoNBIX

Despite no public indication of Cliff Asness identifying Neurocrine Biosciences (NASDAQ: NBIX) as a significant pick, analysts have shown confidence in the company's potential for growth. Asness, known for his strategic investments, typically reveals his stock preferences through regulatory filings like 13F reports, though these documents are not available in real-time. Analyst consensus suggests a "Moderate Buy" rating on Neurocrine Biosciences, with 24 analysts providing an average one-year target price of $163.91, as reported by ETF Daily News. The company’s stock price targets range between $114.00 and $192.00 per share, indicating a potential rise from its current valuation, according to Market Inference. Neurocrine's future appears optimistic due to several ongoing Phase II clinical trials, with results anticipated in 2024, as highlighted by Morning Strong. These developments could strengthen the company's growth prospects, though investors are advised to align such insights with their individual financial objectives.